Instil Bio Inc. reported its financial results for the first quarter ended March 31, 2025. The company experienced a net loss per share of $4.32, an increase from the $3.74 reported for the same period in 2024. However, on a non-GAAP basis, the net loss per share decreased to $1.32 from $2.39 in the prior year. General and administrative expenses fell to $9.1 million from $12.4 million in the previous year, while research and development expenses decreased to $5.4 million from $7.3 million. Restructuring and impairment charges rose significantly to $16.1 million, compared to $4.3 million the previous year. Instil Bio reported $15.4 million in cash and cash equivalents, $1.0 million in restricted cash, $88.3 million in marketable securities, and $7.2 million in long-term investments as of March 31, 2025. The company expects these resources to fund its current operating plan beyond 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.